The company, currently in the process of going public through a SPAC merger, filed a presentation for investors. It features information regarding its ongoing PERIO 01 and PERIO 02 clinical studies. The studies evaluate the TriNav pressure-enabled drug delivery technology for primary and metastatic liver tumors. It delivers SD-101, a class C toll-like receptor 9 (TLR9) agonist.
Get the full story at our sister site, Drug Delivery Business News.
TriSalus Life Sciences announced today that it enrolled the first patient in its clinical study of a treatment for metastatic uveal melanoma.
The PERIO-01 clinical study evaluates SD-101, an investigational toll-like receptor 9 (TLR9) agonist in adults with metastatic uveal melanoma through intravascular administration into uveal melanoma liver metastasis lesions in combination with checkpoint inhibitors using the novel pressure-enabled drug delivery (PEDD) approach.
Get the full story at our sister site, Drug Delivery Business News.
TriSalus Life Sciences and the University of Texas today announced a collaboration to evaluate the treatment of solid tumors.
The Texas MD Anderson Cancer Center and TriSalus will collaborate on treatments for tumors of the pancreas and liver by integrating interventional delivery of SD-101, an investigational toll-like receptor 9 (TLR9) agonist, in combination with checkpoint inhibition immunotherapy, according to a news release.
Get the full story at our sister site, Drug Delivery Business News.
TriSalus today said it appointed Scott Davie as chief financial officer.
Davie will be responsible for overseeing research and development of the company’s intravascular infusion systems. He will report directly to president and CEO Mary Szela.
“We’re thrilled to add Scott’s deep experience in medical device development and commercialization to the critical work underway at TriSalus. Our PEDD-based products have tremendous promise for treating solid tumors, and under his knowledge and leadership skills, we’re poised to help lead a transformation in cancer care,” Szela said in a news release. “Additionally, his experience in the U.S., Canadian, and Japanese markets is essential to supporting our global development efforts.”
Prior to joining the company, Davie held a number of leadership roles at Medtronic. He has more than 25 years of experience in the medical device industry.
“As someone who’s watched cancer cut family members’ lives s…
TriSalus this week said it appointed Rajesh Mistry as chief financial officer.
Mistry brings more than 15 years of experience to the company. He most recently served as head of corporate development at Option Care Health. He has also held numerous leadership positions at Melinta Therapeutics, Baxter International and A.G. Edwards Capital Markets.
“We are very pleased to have Raj lead our finance team as we work to execute our cell therapy and immunomodulation asset acquisition strategy and transition the company to deliver a combination of cutting-edge therapies to attack solid tumors,” president and CEO Mary Szela said in a news release. “Additionally, his proven strategic, industry and Wall Street expertise further strengthens our leadership team and positions the company for future success and continued growth.”
“I am very excited to join Mary and the TriSalus team in their commitment to transforming the lives of patients suffering from solid tumors. …